Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Abemaciclib in EGFR-mutated NSCLC
NCT04545710Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in non-small cell lung cancer (NSCLC), sponsored by University of California, San Diego. Started Nov 2020; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04545710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545710.